JP2023531451A5 - - Google Patents
Info
- Publication number
- JP2023531451A5 JP2023531451A5 JP2022578663A JP2022578663A JP2023531451A5 JP 2023531451 A5 JP2023531451 A5 JP 2023531451A5 JP 2022578663 A JP2022578663 A JP 2022578663A JP 2022578663 A JP2022578663 A JP 2022578663A JP 2023531451 A5 JP2023531451 A5 JP 2023531451A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- ligand
- cdr
- seq
- delivered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040381P | 2020-06-17 | 2020-06-17 | |
| US63/040,381 | 2020-06-17 | ||
| US202163135998P | 2021-01-11 | 2021-01-11 | |
| US63/135,998 | 2021-01-11 | ||
| US202163152085P | 2021-02-22 | 2021-02-22 | |
| US63/152,085 | 2021-02-22 | ||
| PCT/US2021/037575 WO2021257668A1 (en) | 2020-06-17 | 2021-06-16 | Compositions and methods for treatment of gene therapy patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531451A JP2023531451A (ja) | 2023-07-24 |
| JP2023531451A5 true JP2023531451A5 (https=) | 2024-06-24 |
Family
ID=77127052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578663A Pending JP2023531451A (ja) | 2020-06-17 | 2021-06-16 | 遺伝子療法患者の治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220069A1 (https=) |
| EP (1) | EP4171738A1 (https=) |
| JP (1) | JP2023531451A (https=) |
| KR (1) | KR20230025000A (https=) |
| CN (1) | CN115968302A (https=) |
| AU (1) | AU2021292200A1 (https=) |
| CA (1) | CA3183153A1 (https=) |
| IL (1) | IL299167A (https=) |
| MX (1) | MX2022016528A (https=) |
| TW (1) | TW202214695A (https=) |
| WO (1) | WO2021257668A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| IL325936A (en) * | 2020-01-22 | 2026-03-01 | Spark Therapeutics Inc | Compositions and methods for enhancing or improving transduction of gene therapy vectors and removing or reducing immunoglobulins |
| CA3216004A1 (en) | 2021-04-23 | 2022-10-27 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| EP4409010A1 (en) | 2021-10-02 | 2024-08-07 | The Trustees of The University of Pennsylvania | Novel aav capsids and compositions containing same |
| EP4504797A1 (en) | 2022-04-06 | 2025-02-12 | The Trustees of The University of Pennsylvania | Compositions and methods for treating her2 positive metastatic breast cancer and other cancers |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| EP4634394A2 (en) | 2022-12-17 | 2025-10-22 | The Trustees of The University of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024258961A1 (en) | 2023-06-12 | 2024-12-19 | The Trustees Of The University Of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| TW202516019A (zh) | 2023-06-29 | 2025-04-16 | 賓州大學委員會 | 具中樞神經系統靶向模體的突變aav及含有其之組成物 |
| IL326390A (en) | 2023-08-10 | 2026-04-01 | Univ Pennsylvania | Compositions and methods for treating spinal muscular atrophy |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| EP4699615A1 (en) * | 2024-08-22 | 2026-02-25 | Universität Zürich | Fcrn inhibitor and therapeutic polypeptide |
| CN120272478B (zh) * | 2025-03-28 | 2025-12-09 | 山西医科大学 | 一种抗寨卡病毒的靶点抑制剂、重组基因、表达载体及应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
| US6406861B1 (en) * | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| CA2606378A1 (en) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US20070027438A1 (en) | 2005-07-26 | 2007-02-01 | Frieder Loesel | System and method for compensating a corneal dissection |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US20070292922A1 (en) | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| WO2015081096A2 (en) | 2013-11-26 | 2015-06-04 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
| CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| AU2012262007B2 (en) | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| US20150126589A1 (en) | 2012-06-08 | 2015-05-07 | Ethris Gmbh | Pulmonary Delivery of Messenger RNA |
| AU2014235096B2 (en) | 2013-03-15 | 2020-03-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
| US9527890B2 (en) | 2013-06-18 | 2016-12-27 | The Brigham And Womens's Hospital, Inc. | FC receptor (FcRn) binding peptides and uses thereof |
| PL3253453T3 (pl) | 2015-02-04 | 2020-06-01 | Raichle, Marianne | Sposób wytwarzania mleka o wysokiej zawartości natywnej witaminy d |
| CA2978253A1 (en) * | 2015-03-09 | 2016-09-15 | Argenx Bvba | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES |
| EP3387138B1 (en) | 2015-12-11 | 2022-01-26 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| US20190002915A1 (en) | 2015-12-14 | 2019-01-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulatable antibody expression |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| IL276859B2 (en) | 2018-02-27 | 2025-12-01 | Univ Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
| EP3768695A4 (en) | 2018-02-27 | 2022-04-06 | The Trustees of the University of Pennsylvania | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF |
| WO2020132455A1 (en) | 2018-12-21 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| SG11202111375RA (en) | 2019-04-29 | 2021-11-29 | Univ Pennsylvania | Novel aav capsids and compositions containing same |
| JP7585233B2 (ja) | 2019-04-30 | 2024-11-18 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ポンペ病の治療のために有用な組成物 |
| CN113769058B (zh) * | 2020-06-10 | 2024-09-06 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
-
2021
- 2021-06-16 AU AU2021292200A patent/AU2021292200A1/en active Pending
- 2021-06-16 US US18/002,060 patent/US20230220069A1/en active Pending
- 2021-06-16 CA CA3183153A patent/CA3183153A1/en active Pending
- 2021-06-16 KR KR1020237001712A patent/KR20230025000A/ko active Pending
- 2021-06-16 IL IL299167A patent/IL299167A/en unknown
- 2021-06-16 WO PCT/US2021/037575 patent/WO2021257668A1/en not_active Ceased
- 2021-06-16 JP JP2022578663A patent/JP2023531451A/ja active Pending
- 2021-06-16 CN CN202180050281.XA patent/CN115968302A/zh active Pending
- 2021-06-16 EP EP21748696.8A patent/EP4171738A1/en active Pending
- 2021-06-16 TW TW110121993A patent/TW202214695A/zh unknown
- 2021-06-16 MX MX2022016528A patent/MX2022016528A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531451A5 (https=) | ||
| JP6091435B2 (ja) | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 | |
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| JP2019501115A (ja) | 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与 | |
| EA037980B1 (ru) | Рекомбинантный аденоассоциированный вирус | |
| KR20220011664A (ko) | 변형된 바이러스 입자 및 이의 용도 | |
| JP2009532025A (ja) | アデノ関連ウイルスベクターからの組換えタンパク質の制御された発現 | |
| US20190002915A1 (en) | Compositions and methods for regulatable antibody expression | |
| US20240148903A1 (en) | Delivery of antibody by using dual viral vector system | |
| US20230175015A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| US20240092885A1 (en) | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same | |
| CN117242183A (zh) | 用于治疗与血管生成相关的眼部疾病的组合物和方法 | |
| US10946094B2 (en) | Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer | |
| EP4410988A1 (en) | An aav2-vector variant for targeted transfer of genes | |
| TW202400796A (zh) | 雙向雙重啟動子表現載體及其用途 | |
| US20260043046A1 (en) | Cassettes of anti-complement component 3 antibody, vectorization and theraputic application | |
| US20240216535A1 (en) | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof | |
| WO2022072829A1 (en) | Compositions for intranasally delivered passive immunization for airborne pathogens | |
| JP2025512121A5 (https=) | ||
| WO2025076091A1 (en) | Cd20 antibody aav vectors and methods of use thereof | |
| WO2024054993A1 (en) | Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same | |
| HK40092158A (zh) | 一种用於过敏性疾病的基因治疗载体核酸构建体及其使用方法 | |
| HK40092158B (zh) | 一种用於过敏性疾病的基因治疗载体核酸构建体及其使用方法 |